ArticleCureus2025
Methylene Blue for the Treatment of Refractory Hypotension in Polysubstance Overdose.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylene blue is commonly used for methemoglobinemia and vasoplegia following coronary artery bypass procedures but has recently been investigated as a treatment for refractory hypotension. One such cause of refractory hypotension is overdose of calcium channel blocker medications. This case presents a patient with polysubstance overdose and refractory hypotension that improved with methylene blue infusion. This 67-year-old female presented to the ED following an intentional toxic ingestion of multiple substances, including metoprolol, amlodipine, mirtazapine, pantoprazole, quetiapine, levetiracetam, melatonin, and levothyroxine. The patient's hypotension remained unresponsive to fluids, calcium chloride, calcium gluconate, and multiple pressure support medications, including norepinephrine, epinephrine, vasopressin, and phenylephrine. Insulin and dextrose, as well as methylene blue were initiated for severe refractory hypotension unresponsive to other measures. Methylene blue inhibits guanylate cyclase, which decreases the production of cyclic guanosine monophosphate. This, in turn, inhibits vascular smooth muscle relaxation and can be an effective method for refractory hypotension. Therefore, methylene blue can be used for the treatment of refractory vasoplegia unresponsive to other methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.